Library of Slides and Posters Hepatitis B Slides and Posters   (7) Hepatitis C Slides and Posters   (24)
	Hepatitis B Articles
	Hepatitis C Articles

CME/CE Talking Slides Update

EASL 2009 CME/CE Independent Coverage of EASL 2009: Talking Slides Update Program Details

CME/CE NEWSLETTER

EASL 2009 CME/CE Assessing Best Practices in HBV Therapy 2009 CME/CE Newsletter Update Program Details

Library of Slides and Posters

Hepatitis B Slides and Posters Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D Tenney and others. EASL 2009. Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment N Leung and others. EASL 2009   Hepatitis B Virus Drugs in Pregnancy: Findings from the Antiretroviral Pregnancy Registry R Brown and others. EASL 2009. Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis M Buti and others. EASL 2009. Evolution of Viral Load and Genome Sequence in a Clinical Trial of Tenofovir/Emtricitabine Combination Versus Tenofovir Monotherapy for Patients with Previous Adefovir Dipivoxil Failure F Lavocat and others. EASL 2009. Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil T Berg and others. EASL 2009. Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) E Heathcote and others. EASL 2009. Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients M Manns and others. EASL 2009. Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) P Marcellin and others. EASL 2009.   Hepatitis C Slides and Posters IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study X Zhou and others. EASL 2009. Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees D Standring and others. EASL 2009. HCV SPRINT-1 Final Results SVR 24Boceprevir* plus PegIFN alfa-2b/Ribavirin HCV 1 Treatment Naïve Patients P Kwo and others. EASL 2009. SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS H Reesink and others. EASL 2009. Hemoglobin Decline Associated with SVR Among HCV G1-Infected Persons: Analysis from the IDEAL Study M Sulkowski and others. EASL 2009. PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial J Bruix and others. EASL 2009. Extended Treatment Duration in Chronic Hepatitis C Genotype 1 Infected Slow-Responders: Final Results of the SUCCESS Study M Buti and others. EASL 2009. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial)Final Analysis M Manns and others. EASL 2009. OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype-1 HCV patients M Manns and others. EASL 2009. Antiviral activity and safety of TMC435 combined with peginterferon -2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy P Marcellin and others. EASL 2009.   Impact of the Use of Drugs and Substitution Treatments on the Antiviral Treatment of Chronic Hepatitis C: Analysis of Compliance, Virological Response and Quality of Life (CHEOBS) P Melin and others. EASL 2009. Assessing the Role of Chronic Hepatocellular Inflammation in Transformation to Cancer among Hepatic Resection Recipients with HBV Associated HCC S Hiotis and others. EASL 2009. Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers F Höppener and others. EASL 2009. Preclinical Characterization of SCH 900518, A Novel Mechanism-Based Inhibitor of HCV NS3 Protease X Tong and others. EASL 2009. A Regional Gastrointestinal Absorption Study of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers E Hughes and others. EASL 2009. SPRINT-1 Study Design- Boceprevir Schering-Plough. EASL 2009. SPRINT-2 Design (Naïve Study) - Boceprevir Schering-Plough. EASL 2009. SCH 900518 Tablet Study Diagram (Phase 2) - Boceprevir Schering-Plough. EASL 2009. RESPOND-2 Study Design (Treatment Failure Trial) - Boceprevir Schering-Plough. EASL 2009. Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor S Good and others. EASL 2009. Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors LLallos and others. EASL 2009. Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) C Sarrazin and others. EASL 2009. FibroTest™ Is an Independent Predictor of Early and Sustained Virologic Response in Nonresponder Patients With Chronic Hepatitis C: Results From the EPIC3 Study T Poynard and others. EASL 2009. MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection M Manns and others. EASL 2009.

Top       Hepatitis C Articles

Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C Hepatitis C Treatment Is More Successful before Progression to Advanced Liver Damage Data on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents Chronic Hepatitis C Patients with Metabolic Syndrome Are at Greater Risk of Death Extended 72-week Treatment with Pegylated Interferon plus Ribavirin did not Improve Outcomes among Slow Responder Hepatitis C Patients Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3) Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients

Top       Hepatitis B Articles

Factors Associated with Development of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Does HBV Viral Load Level Predict Development of Liver Fibrosis? Researchers Present Data on Investigational Cyclophilin Inhibitors Debio 025 and SCY-635 Investigational 2-Dose Dynavax Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine Telbivudine (Tyzeka) Continues to Produce Good Results for Chronic Hepatitis B Patients after 3 Years Tenofovir (Viread) Is Similarly Effective in Chronic Hepatitis B Patients Regardless of Liver Cirrhosis Status Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B Half of HBeAg Negative Chronic Hepatitis B Patients Maintain Response up to 5 Years after Stopping Long-term Adefovir (Hepsera) Chronic Hepatitis B Patients Who Had Incomplete Response or Relapse on Adefovir (Hepsera) Respond Well to Entecavir (Baraclude) Safety and Efficacy of 96 Weeks of Tenofovir (Viread) in Chronic Hepatitis B Patients Previously Treated with Lamivudine (Epivir-HBV)

Top       HIV-HCV or HIV-HBV Coinfection Articles

HIV-HCV Coinfected Individuals and those with HIV-HBV-HCV Triple Infection Have a Higher Risk of Death in the HAART Era Antiviral Agents with Activity against Both HIV and Hepatitis C Virus Sustained Response to Interferon-based Therapy for Hepatitis C Reduces Risk of Liver Toxicity due to Antiretroviral Drugs for HIV HIV Negative Individuals with Hepatitis C and HIV-HCV Coinfected Patients Have Similar Hepatocellular Carcinoma Outcomes Studies Find No Evidence of Hepatitis C Virus Relapse or Significant Fibrosis after Spontaneous Clearance in HIV-HCV Coinfected Individuals Mechanisms of Accelerated Fibrosis in HIV-HCV and HIV-HBV Coinfected Individuals Laboratory Study Shows Hepatitis B Drug Entecavir (Baraclude) -- But Not Telbivudine (Tyzeka) -- Has Activity against Multiple Strains of HIV Combination Antiretroviral Therapy is Well-tolerated and Rapidly Suppresses HBV Viral Load in HIV-HBV Coinfected Patients HIV Positive and HIV Negative Patients Have Similar Survival Rates after Liver Transplantation, but HCV Recurrence Remains a Risk

15th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Coverage by HIV and Hepatitis.com - February 8 - 11, 2009, Montreal
HIV and AIDS Treatment News, Experimental News, FDA-approved News

Highlights of the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2009) - Coverage by HIV and Hepatitis.com, February 8 - 11, 2009, Montreal